Generics giants jostle over pain drug


The US Food and Drug Administration (FDA) has approved the first batch of generic competitors to Pfizer’s non-steroidal anti-inflammatory Celebrex (celecoxib). Teva received approval for its 50, 100, 200 and 400mg doses, and Mylan also had its 50mg dose approved. Actavis, which was also in the running, is yet to receive final approval for any of its celecoxib generics.

The agency has also granted Teva 180 days’ market exclusivity for all but the 50mg form, under US provisions designed to encourage generic competition. Both Mylan and Actavis have attempted to sue the FDA for this decision, which Mylan has called an ‘unprecedented error’ and Actavis described in a statement as ‘arbitrary, capricious and contrary to law’. The court denied Mylan’s injunction, but the company has signalled its intention to appeal that decision.

Mylan has also negotiated an agreement with Pfizer to launch its generic versions in December 2014, or earlier under certain conditions. All three companies now have such agreements in place.


Related Content

Mylan to buy Meda in further generics consolidation

12 February 2016 Business

news image

£6.9bn deal will give combined company ‘critical mass’ in US market

Generics triumph in anti-inflammatory patent battle

25 April 2014 Business

news image

Pfizer settles deals to allow copycat celecoxib

Most Commented

China’s science enterprise challenging US leadership

26 January 2016 News and Analysis

news image

40% of the world’s R&D is now carried out in south-east, south and east Asia 

Confirmation of four new elements completes seventh row of periodic table

7 January 2016 News and Analysis

news image

Iupac endorse discovery of elements 113, 115, 117 and 118 by teams in Russia, Japan and the US